Observe Medical Asa · OSL:OBSRV
Observe Medical Asa — Investor Presentation (March 2026)
20 slides from Observe Medical Asa's investor presentation, Mar 25, 2026
Slide 1: Company presentation with trading update
Company presentation with trading update 25 March 2026 Jørgen Mann, CEO
Slide 2: Disclaimer (1/2)
Disclaimer (1/2) THIS PRESENTATION IS NOT FOR PUBLICATION NOR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA OR THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATED AND THE DISTRICT OF COLUMBIA) OR ANY OTHER JURISDICTIO
Slide 3: Disclaimer (2/2)
Disclaimer (2/2) This Presentation is intended to present background information on the Company and its business and is not intended to provide complete disclosure upon which an investment decision could be made. Should the Company choose to pursue an offering of its securities in Norway or elsewher
Slide 4: Strategic Vision
Strategic Vision
Slide 5: Nordic Medtech Platform − with global reach
Strategic Vision: Nordic Medtech Platform − with global reach Scalable and profitable growth, product development, regulatory performance and effective manufacturing Proprietary Platform for innovative products Nordic ecosystem Commercialisation and portfolio Start-ups with limited access to develop
Slide 6: Observe Medical: Nordic medtech company with global reach
Observe Medical Nordic medtech company with global reach Strong Medtech Portfolio UnoMeter family Scalable Platform Manufacturing Product Development Sales & Distribution Quality & Regulatory 6
Slide 7: Trading Update
TRADING UPDATE
Slide 8: Gaining momentum into 2026
Gaining momentum into 2026 Quarterly sales* LTM Quarterly sales* Quarterly order intake* 21.670 7.631 8.504 2.483 750 964 1.199 4.748 +60% +73% +80% 2.206 4.772 12.009 182 4.906 195 1.648 687 4.060 5.420 14.097 5.194 4.928 4.023 2.942 3.021 0 342 0 262 0 140 Q1 25 Q1 26e Q1 25 Q1 26e Q1 25 Q1 26e •
Slide 9: Product Development and Roadmap
PRODUCT DEVELOPMENT AND ROADMAP
Slide 10: UnoMeter Safeti Max with successful clinical study, ready for commercial launch
UnoMeter Safeti Max with successful clinical study, ready for commercial launch • In-Vitro clinical study successfully completed on external accredited laboratory – ambitious objectives on claims have been met • Publication of clinical claims in preparation with external clinical team • CE Certficat
Slide 11: Taking the position as the global leader for high end innovative Urine Output Measurement
Taking the position as the global leader for high end innovative Urine Output Measurement solutions Upsell Sippi and Safeti Max to existing Expand portfolio to Recapture the market through UnoMeter family of products clients at higher price points and better allow access to full margins market poten
Slide 12: Expanding market potential UnoMeter A4, A6 and UnoMeter 400
Expanding market potential UnoMeter A4, A6 and UnoMeter 400 • Adding a portfolio with a market potential of NOK 1.6- 1.8bn. • Increased offering and leverage to our distributors • Capitalizing on the UnoMeter brand position • Potential platform for UnoSafeCoat technology • Prepare further geographic
Slide 13: The UnoMeter family - Strengthening our market offering
The UnoMeter family - Stengthening our market offering • Increasing addressable market value from NOK ~670m to NOK ~2.6bn. • Strengthening our strategic position • Managing price pressure UnoMeter 500 UnoMeter Safeti Plus UnoMeter Safeti Max through innovation • Prepare further geographical expansio
Slide 14: UnoMeter Sippi® − next generation technology
UnoMeter Sippi® − next generation technology • Meeting the challenge in Intensive Care: • Clinical study on UnoSafeCoat (prev. SippCoat ) technology has confirmed Sippi’s clinical potential • CE certified • Market demand and potential remains unchanged – increased interest from distributors • Bring
Slide 15: We have expanded the addressable global market from NOK ~670m to ~2.6bn
We have expanded the addressable global market from NOK ~670m to ~2.6bn Sippi® to expand market to ~5bn Market value with UnoMeter Sippi® fully implemented NOK 5+ bn Value of market - manual systems and closed system bags NOK ~2.6bn Value of current market manual systems OM Design NOK ~670m 15
Slide 16: Operational Capacity to Deliver
Operational Capacity to Deliver
Slide 17: Increasing Operational Capacity to Execute
Increasing Operational Capacity to Execute After rightsizing the organisation and corporate structure – we are now building our capacity to execute on our commercial strategy • Sales Director, responsible for sales through existing and new distributors • Product Manager, responsible for Clinical com
Slide 18: Summary
Summary Keone
Slide 19: Global distribution with a network of distributors established in 46 countries
46 Global distribution with a network of distributors established in 46 countries 27 Highly qualified & relevant distributors globally →7 Strategically expanded product portfolio from 3 to 7 products 2.6bn Total addressable market – from NOK ~670m to ~2.6bn LTM YoY 80% growth quarterly sales. Growth
Slide 20: Slide 20